• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Proman David

    2/6/24 9:10:58 PM ET
    $APXI
    Blank Checks
    Finance
    Get the next $APXI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Proman David

    (Last) (First) (Middle)
    C/O APX ACQUISISTION CORP. I
    714 WESTVIEW AVENUE

    (Street)
    NASHVILLE TN 37205

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    APx Acquisition Corp. I [ APXI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/05/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B ordinary shares(1) (1) 09/05/2023 S 20,000 (1) (1) Class A ordinary shares 20,000 $0 0 D
    Explanation of Responses:
    1. Represent founder shares, classified as Class B ordinary shares. Such shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the initial business combination on a one-for-one basis, subject to adjustment, as described in the Form S-1 filed with the U.S. Securities and Exchange Commission on November 19, 2021.
    /s/ David Proman 02/06/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units

    NASHVILLE, Tenn., Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice"). The Company subsequently submitted a plan to regai

    11/1/24 5:48:00 PM ET
    $APXI
    Blank Checks
    Finance

    APX Acquisition Corp. I Reports 10-K Delinquency Notice

    NASHVILLE, Tenn., June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financi

    6/5/24 1:33:00 PM ET
    $APXI
    Blank Checks
    Finance

    APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

    NASHVILLE, Tenn., March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ:APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subject to the approval of APx's shareholders and other customary closing conditions and, upon closing, OmnigenicsAI's shares are expected to be listed on Nas

    3/26/24 8:25:00 AM ET
    $APXI
    Blank Checks
    Finance

    $APXI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by APx Acquisition Corp. I

    SCHEDULE 13G - APx Acquisition Corp. I (0001868573) (Subject)

    1/7/25 4:31:51 PM ET
    $APXI
    Blank Checks
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by APx Acquisition Corp. I

    SCHEDULE 13G/A - APx Acquisition Corp. I (0001868573) (Subject)

    1/7/25 11:47:26 AM ET
    $APXI
    Blank Checks
    Finance

    SEC Form 8-K filed by APx Acquisition Corp. I

    8-K - APx Acquisition Corp. I (0001868573) (Filer)

    12/16/24 4:05:25 PM ET
    $APXI
    Blank Checks
    Finance

    $APXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Bransfield Kyle P disposed of 100,000 units of Class A ordinary shares and acquired 100,000 units of Class A ordinary shares (SEC Form 4)

    4 - APx Acquisition Corp. I (0001868573) (Issuer)

    7/31/24 9:45:03 PM ET
    $APXI
    Blank Checks
    Finance

    Bransfield Kyle P disposed of 800,000 units of Class A ordinary shares and acquired 800,000 units of Class A ordinary shares (SEC Form 4)

    4 - APx Acquisition Corp. I (0001868573) (Issuer)

    3/25/24 5:00:06 PM ET
    $APXI
    Blank Checks
    Finance

    Bransfield Kyle P converted options into 3,342,188 units of Class A ordinary shares (SEC Form 4)

    4 - APx Acquisition Corp. I (0001868573) (Issuer)

    2/8/24 9:05:08 PM ET
    $APXI
    Blank Checks
    Finance

    $APXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by APx Acquisition Corp. I

    SC 13G - APx Acquisition Corp. I (0001868573) (Subject)

    11/14/24 8:51:50 PM ET
    $APXI
    Blank Checks
    Finance

    SEC Form SC 13G filed by APx Acquisition Corp. I

    SC 13G - APx Acquisition Corp. I (0001868573) (Subject)

    11/14/24 4:18:23 PM ET
    $APXI
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by APx Acquisition Corp. I

    SC 13G/A - APx Acquisition Corp. I (0001868573) (Subject)

    10/16/24 9:19:30 AM ET
    $APXI
    Blank Checks
    Finance